FDA-cleared profile

Heuron ICH

Heuron Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Triage and notification of suspected intracranial hemorrhage on non-contrast head CT in adults and transitional adolescents aged 18 years and older, to assist prioritization while full images remain subject to standard-of-care interpretation.

Clinical role
Notification-only triage in parallel with standard-of-care interpretation; suspected cases are prioritized without altering images, removing cases from the reading queue, or replacing full-image review.
Images and patients
CT/CTA · Head/brain
Key limitation
Keep in mind: The compressed preview is not for diagnostic use and the software is not a diagnostic device. Notified specialists must review the full original NCCT under standard of care; original images are not modified and cases are not removed or deprioritized. The FDA indication is NCCT head ICH triage, not CTA or autonomous diagnosis.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Triage and notification of suspected intracranial hemorrhage on non-contrast head CT in adults and transitional adolescents aged 18 years and older, to assist prioritization while full images remain subject to standard-of-care interpretation.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head/brain Input: DICOM non-contrast head CT images for adults or transitional adolescents aged 18 years and older; the device receives images automatically from registered or whitelisted PACS connections and does not query PACS to retrieve images.
  • Who uses it?Intended users: Appropriately trained medical specialists and hospital networks
  • What does the software produce?Output: Notification of suspected positive ICH cases with compressed preview images for information and notification only; no segmentation, intermediate analysis, or image marking is provided. Notifications may be sent through PACS, workstation, email, mobile SMS, and push notification.
  • What is its most important limitation?Key limitation: The compressed preview is not for diagnostic use and the software is not a diagnostic device. Notified specialists must review the full original NCCT under standard of care; original images are not modified and cases are not removed or deprioritized. The FDA indication is NCCT head ICH triage, not CTA or autonomous diagnosis.

Clinical takeaway. Clinical role: Triage and notification of suspected intracranial hemorrhage on non-contrast head CT in adults and transitional adolescents aged 18 years and older, to assist prioritization while full images remain subject to standard-of-care interpretation.

Evidence takeaway. Evidence from the reviewed source record: FDA K233247 reports a retrospective multicenter study of 600 NCCT images from three US hospitals, with 46.2% ICH-positive and 53.8% negative cases. Ground truth used two US board-certified neuroradiologists with third-reader adjudication. Primary sensitivity was 86.3% (95% CI 81.9-90.3) and specificity was 87.6% (95% CI 83.9-91.0); secondary results included NPV 88.1%, PPV 85.6%, AUC 0.945, and time-to-notification 60.3 +/- 39.3 seconds (range 9-161 seconds).

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Triage and notification of suspected intracranial hemorrhage on non-contrast head CT in adults and transitional adolescents aged 18 years and older, to assist prioritization while full images remain subject to standard-of-care interpretation.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Notification-only triage in parallel with standard-of-care interpretation; suspected cases are prioritized without altering images, removing cases from the reading queue, or replacing full-image review.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM non-contrast head CT images for adults or transitional adolescents aged 18 years and older; the device receives images automatically from registered or whitelisted PACS connections and does not query PACS to retrieve images.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Notification of suspected positive ICH cases with compressed preview images for information and notification only; no segmentation, intermediate analysis, or image marking is provided. Notifications may be sent through PACS, workstation, email, mobile SMS, and push notification.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Hospital networks
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Appropriately trained medical specialists and hospital networks
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The compressed preview is not for diagnostic use and the software is not a diagnostic device. Notified specialists must review the full original NCCT under standard of care; original images are not modified and cases are not removed or deprioritized. The FDA indication is NCCT head ICH triage, not CTA or autonomous diagnosis.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K233247 reports a retrospective multicenter study of 600 NCCT images from three US hospitals, with 46.2% ICH-positive and 53.8% negative cases. Ground truth used two US board-certified neuroradiologists with third-reader adjudication. Primary sensitivity was 86.3% (95% CI 81.9-90.3) and specificity was 87.6% (95% CI 83.9-91.0); secondary results included NPV 88.1%, PPV 85.6%, AUC 0.945, and time-to-notification 60.3 +/- 39.3 seconds (range 9-161 seconds).
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K233247 reports a retrospective multicenter study of 600 NCCT images from three US hospitals, with 46.2% ICH-positive and 53.8% negative cases. Ground truth used two US board-certified neuroradiologists with third-reader adjudication. Primary sensitivity was 86.3% (95% CI 81.9-90.3) and specificity was 87.6% (95% CI 83.9-91.0); secondary results included NPV 88.1%, PPV 85.6%, AUC 0.945, and time-to-notification 60.3 +/- 39.3 seconds (range 9-161 seconds).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
86.3% (95% CI: 81.9%, 90.3%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
87.6% (95% CI: 83.9% - 91.0%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Heuron ICH regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K233247
  • Samplen=600
  • Sites3
  • IndependenceIndependence not established

K233247

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233247. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM non-contrast head CT images for adults or transitional adolescents aged 18 years and older; the device receives images automatically from registered or whitelisted PACS connections and does not query PACS to retrieve images.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K233247: Heuron ICH

  2. Routing

    Source context, not route validation: The packet specifies PACS registration using IP, port, AE title, and TLS authentication, DICOM receipt through an allowlisted PACS connection, a dedicated server/worklist, and notification channels including PACS, workstation, email, SMS, and push. Specific current deployment details and interface versions are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K233247: Heuron ICH

  3. AI processing

    Source context, not route validation: The exact FDA package describes DICOM images transmitted from PACS being uploaded to the Heuron ICH server, where they are analyzed in order of reception and become accessible through a worklist. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Once the DICOM images transmitted from PACS are uploaded to the Heuron ICH server, the images become accessible through the worklist." … "Images received by Heuron ICH server are analyzed in the order of reception.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K233247: Heuron ICH

  4. Returned objects

    Source context, not route validation: Notification of suspected positive ICH cases with compressed preview images for information and notification only; no segmentation, intermediate analysis, or image marking is provided. Notifications may be sent through PACS, workstation, email, mobile SMS, and push notification.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K233247: Heuron ICH

  5. Viewer/worklist/report

    Unresolved route: Notification of suspected positive ICH cases with compressed preview images for information and notification only; no segmentation, intermediate analysis, or image marking is provided. Notifications may be sent through PACS, workstation, email, mobile SMS, and push notification.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K233247: Heuron ICH

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes DICOM images transmitted from PACS being uploaded to the Heuron ICH server, where they are analyzed in order of reception and become accessible through a worklist. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Once the DICOM images transmitted from PACS are uploaded to the Heuron ICH server, the images become accessible through the worklist." … "Images received by Heuron ICH server are analyzed in the order of reception.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The packet specifies PACS registration using IP, port, AE title, and TLS authentication, DICOM receipt through an allowlisted PACS connection, a dedicated server/worklist, and notification channels including PACS, workstation, email, SMS, and push. Specific current deployment details and interface versions are not established.
  • Exact FDA submission
  • Checked 2026-09-08

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Heuron ICH; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233247
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Head/brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-05-15
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K233247 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K233247: Heuron ICH

    U.S. Food and Drug Administration - Published 2024-05-15 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Heuron ICH model card (K233247)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K233247

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K233247 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K190424

HealthICH

Zebra Medical Vision Ltd.

Authorized purpose: Case-level triage of adult non-contrast head CT examinations with features suggestive of intracranial hemorrhage (ICH); not a diagnostic or rule-out tool.

Modality
CT/CTA
Anatomy
Head/brain
Decision
2019-06-13
FDA-cleared K261317

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Adult head CTA or mCTA triage for suspected complete large-vessel and medium-vessel occlusion.

Modality
CT/CTA
Anatomy
Head/Brain
Decision
2026-05-14
FDA-cleared K252421

JLK-NCCT

JLK, Inc.

Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.

Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Decision
2026-03-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history